BG
SLN

Bellevue Group’s Silence Therapeutics SLN Stock Holding History

Bellevue Group’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30,483
Closed -$361K – 184
2022
Q2 		$361K Sell
30,483
-16,183
-35% -$197K 0.01% 150
2022
Q1 		$887K Hold
46,666
– – 0.01% 152
2021
Q4 		$1.09M Buy
+46,666
New +$1.08M 0.01% 154

Other funds holding SLN

LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
LOAME
Lombard Odier Asset Management (Europe) London, United Kingdom $1.85B AUM 27.05% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Bellevue Group's SLN Position: Q3 2022 in Review

Bellevue Group sold out of Silence Therapeutics (SLN) in Q3 2022, closing a stake of 30,483 shares — an estimated $361K sold.

Bellevue Group first reported a position in SLN in Q4 2021 and held it in 3 quarters. The position peaked at $1.09M in Q4 2021. 29 funds tracked by Wall St. Rank hold SLN as of Q3 2022.

  • Bellevue Group reported no remaining Silence Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Bellevue Group sold 30,483 Silence Therapeutics shares in Q3 2022, an estimated $361K.
  • Bellevue Group first reported a position in Silence Therapeutics in Q4 2021 and held it in 3 quarters.
  • Bellevue Group's Silence Therapeutics position peaked at $1.09M in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2022.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.